Skip to main content
Year archive

BioPorto — 2022 filings

All 24 regulatory filings released by BioPorto (BIOPOR) in 2022, sourced directly from the official regulator.

24 Filings
2022 Period
2022 filings (24)
Filing Released Lang
Regulatory Filings 2022
Regulatory Filings
2022-11-10 English
Correction: BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration
Regulatory Filings
2022-11-10 English
Regulatory Filings 2022
Regulatory Filings
2022-11-10 English
BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration
Regulatory Filings
2022-11-10 English
Earnings Release 2022
Earnings Release H1 2022
2022-09-08 English
BioPorto Announces Interim Results for the First Six Months of 2022
Interim / Quarterly Report H1 2022
2022-09-08 English
Regulatory Filings 2022
Regulatory Filings
2022-06-28 English
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.
Regulatory Filings
2022-06-28 English
Annual Report (ESEF) 2021
Annual Report (ESEF) FY 2021
2022-04-06 English
Report Publication Announcement 2022
Report Publication Announcement
2022-04-06 English
BioPorto Publishes 2021 Annual Report  
Remuneration Information
2022-04-06 English
BioPorto Publishes 2021 Annual Report  
Annual Report FY 2021
2022-04-06 English
Director's Dealing 2022
Director's Dealing
2022-04-01 English
Director's Dealing 2022
Director's Dealing
2022-04-01 English
Managers’ transactions
Director's Dealing
2022-04-01 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-04-01 English
Major Shareholder Announcement
Major Shareholding Notification
2022-04-01 English
BioPorto A/S announces completion of rights issue; capital raised, total number of shares, and voting rights
Share Issue/Capital Change
2022-04-01 English
BioPorto A/S announces completion of rights issue; capital raised, total number of shares, and voting rights
Share Issue/Capital Change
2022-04-01 Danish
Approval of prospectus for BIOPORTO A/S; Shares
Share Issue/Capital Change
2022-03-08 English
Capital/Financing Update 2022
Capital/Financing Update
2022-03-07 English
BioPorto A/S publishes prospectus in connection with a rights issue with pre-emptive subscription rights for its existing shareholders
Capital/Financing Update
2022-03-07 Danish
Share Issue/Capital Change 2022
Share Issue/Capital Change
2022-03-07 English
BioPorto announces intention to initiate a rights issue with expected gross proceeds of up to approximately DKK 100.4M, updates on status of The NGAL Test clinical trials, and announces its financial
Capital/Financing Update
2022-03-07 Danish